New Delhi: Tata Memorial Center, located in Mumbai, has developed a new drug for cancer treatment in the country. Priced at ₹100 per tablet, this medicine will reduce the risk of cancer in patients treated with radiotherapy or chemotherapy. The research for the past 10 years has led to the successful development of this drug by the institution's researchers and doctors. According to a received report, after a decade of hard work, this drug has been successfully developed.

It will not only reduce the chances of cancer recurrence in patients who have undergone cancer treatment but also decrease the side effects of chemotherapy or radiotherapy by 50 percent. During an interview, senior surgeon Rajendra Badwe explained the development of this drug, "Human cancer cells were implanted into mice for this research, which resulted in them getting cancer. Subsequently, the mice were treated with radiotherapy, chemotherapy, and surgery. It was found that after death, cancer cells break down, referred to as chromatin particles. These particles can travel to other parts of the body with blood and can infect normal cells when they enter them, potentially causing cancer."

To address this problem, researchers administered resveratrol and copper (copper) mixed pills to the mice that were successfully treated. These pills release oxygen quickly. As a result, chromatin particles die. This drug will prevent cancer recurrence by 50 percent and provide up to 30 percent protection against initial cancer occurrence. It could also be used for the treatment of oral and throat cancers.

Dr. Badwe revealed, "Doctors at Tata Institute have been working on this drug for almost a decade. Approval for this drug is pending from the Food Safety and Standards Authority of India (FSSAI). Scientists at the Tata Institute of Fundamental Research (TIFR) have applied for it. Once approved, it could be available in the market from June-July. This drug will significantly facilitate cancer treatment." He noted that while millions or even billions of rupees are currently spent on cancer treatment, the price of this drug will be only ₹100 per tablet. He mentioned that it has been tested on mice so far and its effects on humans will be observed over the next five years.

AAP releases list of Lok Sabha candidates in Delhi: Find out who got the ticket where?

Forgot the BJP alliance? Congress leader Dikshit's sharp reply

Congress Raises Alarm Over Alleged BJP Interference in Party Finances